A NGIO competitor $GLSI has been active with the CEO participating in bio and financial investor conferences plus presenting scientific data in 2 abstracts at the upcoming AACR cancer conference. I was looking at the abstract titles hoping to see something for AE37 such as the ten year data. GLSI’s abstracts are again for five year data on the GP2 her2 vaccine, although they are really cherry picking to a comical degree (yet the market rewards them with a few hundred mil valuation.) The AE37 ten year data deserves to be presented which in turn boosts the valuation of the company if the news is properly received. ASCO is next after AACR. It sure would be nice to see AE37 discussed there again like years ago. Getting NGIO spun out onto Nasdaq, as GLSI was, will be the big help so we can see the company funded and properly represent and promote themselves- hopefully there’s a professional virtual road show planned for NGIO.

https://investor.greenwichlifesciences.com/ne...s-releases